A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Trial Identifier: 8690-002
Sponsor: Merck
Start Date: March 2026
Primary Completion Date: October 2027
Study Completion Date: December 2028
Condition: IBD

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Korea, Republic of, Kang-won-do Wonju-si, Kang-won-do, Korea, Republic of, 26426
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03181
United States, CA Anaheim, CA, United States, 92805
United States, CO Colorado Springs, CO, United States, 80907
United States, CO Englewood, CO, United States, 80113
United States, FL Inverness, FL, United States, 34452
United States, FL Miami, FL, United States, 33134
United States, GA Macon, GA, United States, 31201
United States, KS Kansas City, KS, United States, 66160
United States, LA New Orleans, LA, United States, 70112
United States, MO Liberty, MO, United States, 64068